Texas-based Lexicon Pharmaceuticals Inc. has announced the successful completion of open-label, pioneer portions of the LX4211 trial and is now progressing to a Phase 2, placebo-controlled portion in type 1 diabetic study participants. The dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) is an investigational oral hypoglycemic drug that target type 1 diabetics.
http://bionews-tx.com/news/2013/05/14/lexicon-pharmaceuticals-advances-lx4211-in-type-1-diabetes-phase-2-trial/
No comments:
Post a Comment